These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20074001)

  • 61. Combined Use of MC4PC, MDL-QSAR, BioEpisteme, Leadscope PDM, and Derek for Windows Software to Achieve High-Performance, High-Confidence, Mode of Action-Based Predictions of Chemical Carcinogenesis in Rodents.
    Matthews EJ; Kruhlak NL; Benz RD; Contrera JF; Marchant CA; Yang C
    Toxicol Mech Methods; 2008; 18(2-3):189-206. PubMed ID: 20020914
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Toward a unifying strategy for the structure-based prediction of toxicological endpoints.
    Carrió P; Sanz F; Pastor M
    Arch Toxicol; 2016 Oct; 90(10):2445-60. PubMed ID: 26553148
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Computational toxicology at the European Commission's Joint Research Centre.
    Mostrag-Szlichtyng A; Zaldívar Comenges JM; Worth AP
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):785-92. PubMed ID: 20443752
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunogenicity of therapeutics: a matter of efficacy and safety.
    Nechansky A; Kircheis R
    Expert Opin Drug Discov; 2010 Nov; 5(11):1067-79. PubMed ID: 22827745
    [TBL] [Abstract][Full Text] [Related]  

  • 65. In silico toxicology models and databases as FDA Critical Path Initiative toolkits.
    Valerio LG
    Hum Genomics; 2011 Mar; 5(3):200-7. PubMed ID: 21504870
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In silico ADME prediction: data, models, facts and myths.
    Lombardo F; Gifford E; Shalaeva MY
    Mini Rev Med Chem; 2003 Dec; 3(8):861-75. PubMed ID: 14529504
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of computational methods in pharmaceutical sciences.
    Kortagere S; Lill M; Kerrigan J
    Methods Mol Biol; 2012; 929():21-48. PubMed ID: 23007425
    [TBL] [Abstract][Full Text] [Related]  

  • 68. (Q)SAR modeling and safety assessment in regulatory review.
    Kruhlak NL; Benz RD; Zhou H; Colatsky TJ
    Clin Pharmacol Ther; 2012 Mar; 91(3):529-34. PubMed ID: 22258468
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Computational toxicology: Its essential role in reducing drug attrition.
    Naven RT; Louise-May S
    Hum Exp Toxicol; 2015 Dec; 34(12):1304-9. PubMed ID: 26614820
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Discovery of estrogen receptor modulators: a review of virtual screening and SAR efforts.
    Xu X; Yang W; Li Y; Wang Y
    Expert Opin Drug Discov; 2010 Jan; 5(1):21-31. PubMed ID: 22823969
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Interpretable, probability-based confidence metric for continuous quantitative structure-activity relationship models.
    Keefer CE; Kauffman GW; Gupta RR
    J Chem Inf Model; 2013 Feb; 53(2):368-83. PubMed ID: 23343412
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Chemoinformatics: Achievements and Challenges, a Personal View.
    Gasteiger J
    Molecules; 2016 Jan; 21(2):151. PubMed ID: 26828468
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Enalos Suite: New Cheminformatics Platform for Drug Discovery and Computational Toxicology.
    Varsou DD; Nikolakopoulos S; Tsoumanis A; Melagraki G; Afantitis A
    Methods Mol Biol; 2018; 1800():287-311. PubMed ID: 29934899
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of the Use of QSARS for Priority Setting and Risk Assessment.
    Feijtel TC
    SAR QSAR Environ Res; 1995 Sep; 3(3):237-45. PubMed ID: 22091821
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Idiosyncratic reactions and metabolism of sulfur-containing drugs.
    Zuniga FI; Loi D; Ling KH; Tang-Liu DD
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):467-85. PubMed ID: 22394356
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In silico prediction of ADMET properties: how far have we come?
    Dearden JC
    Expert Opin Drug Metab Toxicol; 2007 Oct; 3(5):635-9. PubMed ID: 17916052
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Consultancy Activity on In Silico Models for Genotoxic Prediction of Pharmaceutical Impurities.
    Pavan M; Kovarich S; Bassan A; Broccardo L; Yang C; Fioravanzo E
    Methods Mol Biol; 2016; 1425():511-29. PubMed ID: 27311479
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds.
    Orogo AM; Choi SS; Minnier BL; Kruhlak NL
    Mol Inform; 2012 Oct; 31(10):725-39. PubMed ID: 27476455
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.
    Issa NT; Wathieu H; Ojo A; Byers SW; Dakshanamurthy S
    Curr Drug Metab; 2017; 18(6):556-565. PubMed ID: 28302026
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Improving the Safety Assessment of Chemicals and Drug Candidates by the Integration of Bioinformatics and Chemoinformatics Data.
    Steger-Hartmann T; Pognan F
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():29-36. PubMed ID: 29316298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.